Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LISATA THERAPEUTICS, INC. (LSTA)

Lisata Therapeutics cuts about 72% of workforce, pursues strategic options, sues Kuva Labs

Negative Impact 4 of 5 restructuring Written later

Lisata Therapeutics approved a reduction in workforce of approximately 72%, effective immediately, as it plans to pursue strategic options and cut ongoing operating expenses. The company expects about $1.2 million in severance and related termination costs through the quarter ending September 30, 2026, and its chief medical officer is departing. The company also sued Kuva Labs over alleged breach of a March 2026 merger agreement, seeking damages for expected stockholder benefits.

Key points

  • Workforce reduction of approximately 72%, effective immediately, approved by the Board on August 3, 2026
  • Estimated costs of approximately $1.2 million, expected through the quarter ending September 30, 2026
  • Dr. Kristen K. Buck, EVP of R&D and Chief Medical Officer, terminated effective August 3, 2026; contractually entitled to 12 months of base salary and target bonus, plus up to 12 months of COBRA premiums, subject to a release
  • Delaware Court of Chancery action filed July 31, 2026 against Kuva Labs Inc. and Kuva Acquisition Corp. over the Merger Agreement dated March 6, 2026

The filing

CompanyLISATA THERAPEUTICS, INC. (LSTA)
Form8-K, current report
Filed with the SECAug 4, 2026, 6:01 AM ET
Accession number0001140361-26-031028

Items reported: 2.05 Exit / Restructuring Costs5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.